Home › Funds › Paradigm Biocapital Advisors LP › MBX
Paradigm Biocapital Advisors LP position in MBX
MBX BIOSCIENCES INC · Health Care
Paradigm Biocapital Advisors LP reported holding 3,772,885 shares of MBX (MBX BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$221.2M, representing 4.40% of its reported portfolio and ranking #7 among its reported holdings. Paradigm Biocapital Advisors LP has disclosed MBX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Paradigm Biocapital Advisors LP's MBX position evolved
Paradigm Biocapital Advisors LP first disclosed a stake in MBX in Q2 2026 at 2,508,015 shares (US$138.4M). The position peaked in Q3 2026 at 3,772,885 shares, worth US$221.2M. Across 2 filings, Paradigm Biocapital Advisors LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 3,772,885 shares valued at US$221.2M — an increase of 1,264,870 shares quarter over quarter.. Notable position changes include a 50% increase in Q3 2026 (shares fell 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 2.51M | $138.44M | New |
| Q3 2026 | 3.77M | $221.17M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MBX and 13F data
MBX (MBX BIOSCIENCES INC) is a Health Care company. 61 other funds we track also report a position in MBX — the largest reported positions include Frazier Life Sciences Management, L.P. (US$367.2M), NEA Management Company, LLC (US$199.5M), ORBIMED ADVISORS LLC (US$189.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MBX
- Frazier Life Sciences Management, L.P. 6.65M sh · $367.19M · Q2 2026
- NEA Management Company, LLC 3.61M sh · $199.52M · Q2 2026
- ORBIMED ADVISORS LLC 3.43M sh · $189.27M · Q2 2026
- NVP Associates, LLC 2.14M sh · $125.23M · Q3 2026
- Aaron Wealth Advisors LLC 1.18M sh · $68.92M · Q3 2026
- Kynam Capital Management, LP 934.80K sh · $54.80M · Q3 2026
- EVENTIDE ASSET MANAGEMENT, LLC 873.49K sh · $51.20M · Q3 2026
- Parkman Healthcare Partners LLC 716.54K sh · $42.00M · Q3 2026
- BRAIDWELL LP 710.88K sh · $39.24M · Q2 2026
- TCG Crossover Management, LLC 650.00K sh · $38.10M · Q3 2026
- Deep Track Capital, LP 640.00K sh · $37.52M · Q3 2026
- Cormorant Asset Management, LP 550.00K sh · $30.36M · Q2 2026
More on Paradigm Biocapital Advisors LP
FAQ
How long has Paradigm Biocapital Advisors LP held MBX?
Paradigm Biocapital Advisors LP has disclosed MBX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Paradigm Biocapital Advisors LP's current position in MBX?
As of Q3 2026, Paradigm Biocapital Advisors LP holds 3.77M shares of MBX (MBX BIOSCIENCES INC), valued at $221.17M, representing 4.40% of its reported portfolio and ranking #7.
Has Paradigm Biocapital Advisors LP been buying or selling MBX?
In the latest 13F filing (Q3 2026), Paradigm Biocapital Advisors LP increased its position in MBX. The position peaked in Q3 2026 at 3.77M shares.
Which other funds hold MBX?
Other major institutional holders of MBX include Frazier Life Sciences Management, L.P., NEA Management Company, LLC, ORBIMED ADVISORS LLC, among 61 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.